EvoNext (EVE.SW, SIX) gains 14.12% to CHF0.97 on 16 Feb 2026: next target CHF1.45

The EVE.SW stock jump led Swiss small-caps on 16 Feb 2026 after EvoNext Holdings S.A. closed at CHF0.97, up 14.12% from the prior close, on 10,527.00 shares traded. The move pushed the price above the 50-day average of CHF0.81 and back near the 200-day average of CHF0.97, signalling renewed buying interest in this Biotechnology name on the SIX exchange. As markets closed, traders flagged the upcoming earnings date and a tight cash position as immediate catalysts for follow-through.

Price action and top-gainer context

EVE.SW stock led intraday gainers on 16 Feb 2026, rising 14.12% to CHF0.97 from an open of CHF0.85 with a day range CHF0.85–CHF0.98. Volume at 10,527.00 represented a relative volume of 1.44, above the 30-day average, which confirms genuine buying interest rather than a low-volume spike. The one-day move reduces the gap to the year high of CHF1.45, making the CHF1.45 level the first clear resistance to monitor.

EVE.SW stock financials and valuation

EvoNext Holdings S.A. shows a market cap of CHF6,995,205.00 and EPS of -0.12, producing a negative PE of -8.08, which reflects losses rather than an overvaluation. Cash per share stands at 0.87 and book value per share is 0.86, giving a price-to-book near 0.98, below many peer medians. Current ratio and cash buffers look strong on paper (current ratio 8.34), but revenue per share is 0.00, so investors should weigh liquidity against limited sales conversion.

EVE.SW stock technicals and momentum

Technical indicators show mixed momentum: RSI at 52.91 suggests neutral momentum while ADX 29.43 points to a developing trend. Short-term overlays place the 50-day average at 0.81 and the 200-day average at 0.97, with Bollinger middle at 0.80 and upper band 0.85. The CCI at 221.05 and MFI at 87.28 are overbought readings that caution on near-term pullbacks despite the strong one-day gain.

Meyka AI rates EVE.SW with a score out of 100 and forecast

Meyka AI rates EVE.SW with a score of 67.90 out of 100 and assigns a Grade B (HOLD). This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, key ratios, forecasts and analyst consensus. Meyka AI’s forecast model projects a yearly level of CHF2.33, a quarterly level near CHF0.91, and a monthly level of CHF0.52. Compared with the current CHF0.97, the yearly projection implies an upside of 140.12%. Forecasts are model-based projections and not guarantees.

Catalysts, risks and healthcare sector context

Key near-term catalyst is the earnings announcement scheduled for 20 Feb 2026, which may crystallise guidance and cash burn metrics. As a biotechnology company in the Healthcare sector on the SIX, EVE.SW stock faces sector dynamics where peers show modest YTD strength; Healthcare 3M performance is 9.37%, and average PB in the sector is 4.20, making EvoNext’s 0.98 PB relatively low. Main risks include ongoing operating losses, limited revenue generation, and low float liquidity (shares outstanding 7,211,552.00).

Price targets, scenarios and practical trading notes

Analyst-style scenarios: a conservative target is CHF1.10 (near short-term resistance and 50–200 day crossover), base case target CHF1.45 (year high), and bullish outcome CHF2.33 per Meyka AI yearly forecast. Short-term traders should watch volume confirmation above 15,000.00 and a close above CHF1.00 for momentum continuation. For investors, valuation metrics (PB ~0.98) and high current ratio support a case for selective accumulation but only with strict risk limits due to negative EPS and low liquidity.

Final Thoughts

EVE.SW stock finished the market session on 16 Feb 2026 as a top gainer, rising 14.12% to CHF0.97 on above-average volume. Technicals show momentum but some overbought short-term signals, while valuation measures such as price-to-book near 0.98 and cash per share 0.87 provide a partial fundamental cushion. Meyka AI’s grading places EVE.SW at 67.90/100 (Grade B, HOLD) after weighing sector comparisons, growth trends and key metrics. Meyka AI’s forecast model projects a yearly level of CHF2.33, implying 140.12% upside versus the close of CHF0.97, but that projection is model-based and not a guarantee. The immediate watchpoints are the earnings release on 20 Feb 2026, intraday volume above 15,000.00, and whether price can clear the CHF1.45 resistance. Given low liquidity and negative EPS, risk management and position sizing are essential for traders and investors considering EVE.SW stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.